W. Ray Kim

Professor and Chief

Stanford University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

W. Ray Kim is a Professor and Chief at Stanford University in the United States. His research areas focus on liver disease, particularly metabolic dysfunction-associated steatotic liver disease, kidney injury in patients undergoing procedures like paracentesis, and the use of machine learning in clinical risk prediction for liver fibrosis. He has contributed to recent articles addressing screening strategies and disparities in liver transplantation, highlighting the importance of a standardized approach in these fields.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

Clinical Associate Professor

Stanford University School of Medicine

UNITED STATES

View details

Sun Kim

Associate Professor

Stanford University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

W. Ray Kim

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance

Albumin prevents kidney injury but is underutilized in a cohort of patients undergoing large-volume paracentesis

Letter to the Editor: How to count from 0 to 4 without skipping a number

Population perspectives on benefits and harms of screening for metabolic dysfunction–associated steatotic liver disease

Optimal Population Screening Strategies for Liver Fibrosis Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease

Steatotic Liver Disease in the US: The Impact of the New Nomenclature on Classification of Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease and Alcohol-Associated Liver Disease

Benchmarking clinical risk prediction algorithms with ensemble machine learning for the noninvasive diagnosis of liver fibrosis in NAFLD

The suggestion of mitigating disparity in the liver transplantation field among ABO blood type

Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda

Common definitions and variables are needed for the United States to join the conversation on acute-on-chronic liver failure

The steatosis‐associated fibrosis estimator (SAFE) score: A tool to detect low‐risk NAFLD in primary care

Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B

Hepatitis C Screening in Post–Baby Boomer Generation Americans: One Size Does Not Fit All

Diagnostic and prognostic performance of the SAFE score in non‐alcoholic fatty liver disease

MELD 3.0 for adolescent liver transplant candidates

Mortality in patients with end‐stage liver disease above model for end‐stage liver disease 3.0 of 40

Response to: “Towards optimally replacing the current version of MELD”

Timely Albumin Improves Survival in Patients With Cirrhosis on Diuretic Therapy Who Develop Acute Kidney Injury: Real-World Evidence in the United States

Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir-vs. entecavir-based regimens: individual patient data meta-analysis

“Beyond MELD” – Emerging strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation

Collaborators (11)

Alice Cheng

Yaron Rotman

Young-Suk Lim

Aparna Goel

lu tian

Patrick T.F. Kennedy

Lewis Roberts

Harriet Cant

Meng Yin

Kazunari Sasaki

Sun Kim

Make your next move.